Serum NfL may be biomarker for MS disease progression


A study presented at the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2021 found that patients with high serum neurofilament light levels at baseline had a 2.6 times greater risk of disease progression at two years. Researcher Dr. Synne Brune said the study suggests serum NfL may be a biomarker for neuroaxonal degeneration, even in early disease stages, while cerebral and retinal atrophy progress more slowly and are more pronounced in later disease stages.

Full story:

SNMMI SmartBrief

Nuclear medicine, molecular imaging and therapy

Designed specifically for nuclear medicine and molecular imaging professionals, SNMMI SmartBrief is a FREE, daily e-mail newsletter. It provides the latest news and information to save you time and keep you informed on our profession.